<SEC-DOCUMENT>0001367644-25-000010.txt : 20250114
<SEC-HEADER>0001367644-25-000010.hdr.sgml : 20250114
<ACCEPTANCE-DATETIME>20250114081313
ACCESSION NUMBER:		0001367644-25-000010
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250114
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250114
DATE AS OF CHANGE:		20250114

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Emergent BioSolutions Inc.
		CENTRAL INDEX KEY:			0001367644
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				141902018
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33137
		FILM NUMBER:		25527814

	BUSINESS ADDRESS:	
		STREET 1:		300 PROFESSIONAL DR
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20879
		BUSINESS PHONE:		240-631-3200

	MAIL ADDRESS:	
		STREET 1:		300 PROFESSIONAL DR
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20879
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ebs-20250114.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:7308415f-beb6-4e39-b0ef-bdca129f68fa,g:bc0f4012-f9b6-42b6-984a-7db61b60311b,d:cb1c371d07334e4ea0f9de3d0e8883c3-->
<html xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ebs-20250114</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0001367644</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-23">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ebs-20250114.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-14</xbrli:startDate><xbrli:endDate>2025-01-14</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="icb1c371d07334e4ea0f9de3d0e8883c3_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">January 14, 2025</ix:nonNumeric></ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-4">EMERGENT BIOSOLUTIONS INC.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.655%"><tr><td style="width:1.0%"/><td style="width:30.791%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.791%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.952%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-5">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">001-33137</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-7">14-1902018</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(IRS Employer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">of incorporation)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identification No.)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-8">300 Professional Drive</ix:nonNumeric>,</span></div><div style="margin-bottom:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-9">Gaithersburg</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-10">Maryland</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-11">20879</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices, including zip code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-12">240</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-13">631-3200</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">N/A</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">see</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> General Instruction A.2. below):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160; Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-17">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div style="margin-bottom:10pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.109%"><tr><td style="width:1.0%"/><td style="width:40.274%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.663%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.763%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-18">Common Stock, $0.001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-19">EBS</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-20">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in&#160;Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-21">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:9pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8.01 Other Events.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 14, 2025, Emergent BioSolutions Inc. (&#8220;Emergent&#8221;) issued a press release announcing an agreement with Hikma Pharmaceuticals Inc. (&#8220;Hikma&#8221;) in which Emergent obtained commercial rights in the United States and Canada to Hikma&#8217;s KLOXXADO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Naloxone HCl) Nasal Spray, an 8 mg naloxone agent.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Hikma will continue to manufacture KLOXXADO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nasal Spray 8 mg, which will be integrated into Emergent&#8217;s proprietary NARCANDirect&#8482; distribution network.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A copy of the press release is filed as Exhibit 99.1 and is incorporated herein by reference.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 9.01 Financial Statements and Exhibits.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (d)         </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exhibits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:12.693%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.917%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.090%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="pressrelease_01142025.htm">Press release issued by Emergent BioSolutions Inc. on </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="pressrelease_01142025.htm">January 14</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="pressrelease_01142025.htm">, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="pressrelease_01142025.htm">5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="pressrelease_01142025.htm">.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.655%"><tr><td style="width:1.0%"/><td style="width:50.182%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.971%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EMERGENT BIOSOLUTIONS INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: January 14, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Richard S. Lindahl</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:  Richard S. Lindahl<br/>Title:  Executive Vice President, Chief Financial <br/>Officer and Treasurer</span></td></tr><tr style="height:39pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>pressrelease_01142025.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ie109525960724954b27ed07821842694_36"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><img alt="imagea.jpg" src="imagea.jpg" style="height:28px;margin-bottom:5pt;vertical-align:text-bottom;width:251px"></div></div><div style="text-align:center"><font style="color:#2c2c29;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO</font><font style="color:#2c2c29;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#2c2c29;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Alongside over-the-counter NARCAN</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Nasal Spray 4 mg, prescription </font><font style="color:#2c2c29;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">KLOXXADO</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(naloxone HCl)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Nasal Spray 8 mg will expand Emergent&#8217;s ability to distribute multiple life-saving opioid overdose emergency treatments to patients, customers and communities in need</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Focus remains on increasing access, raising awareness and ensuring strong supply to meet the ongoing demand of naloxone nasal spray</font></div><div><font><br></font></div><div><font style="color:#2c2c29;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">G</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">AITHERSBURG, Md., Jan. 14, 2025 (GLOBE NEWSWIRE) &#8211; Emergent BioSolutions Inc. (NYSE&#58; EBS) announced today that it has entered into an agreement to obtain exclusive commercial rights in the U.S. and Canada to Hikma Pharmaceuticals&#8217; KLOXXADO</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (naloxone HCl) Nasal Spray, an 8 mg naloxone agent that is approved for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and&#47;or central nervous system depression.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> This six-year agreement complements and strengthens Emergent&#8217;s mission to protect, enhance, and save lives by helping to reduce opioid overdose deaths &#8212;providing compelling product options, combined with a commitment to increasing naloxone access, awareness, and education. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There have been great strides in the fight against the opioid epidemic since 2018 when Emergent first acquired its flagship product, NARCAN</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Nasal Spray, which is designed to rapidly reverse the effects of a life-threatening opioid emergency.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#91;2&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> A recent report from the Centers for Disease Control and Prevention confirms the number of opioid overdose deaths in the U.S. decreased last year &#8211; the first meaningful decline since 2018.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> There are a variety of factors that contributed to this decline&#59; and such progress reinforces the positive impact of Emergent&#8217;s comprehensive national strategy and ongoing efforts to increase access to and awareness of available naloxone nasal spray. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;The initial signs of progress toward stemming the tide of lives lost to opioid overdose are promising. Emergent&#8217;s relentless dedication to working with those on the frontlines of the epidemic, speaking with families and caregivers, and engaging with advocates and other critical stakeholders in the fight, underscores that even one death is too many and our commitment to doing what we can to help remains steadfast,&#8221; said Joe Papa, president and chief executive officer, Emergent. &#8220;Meeting the needs of our patients and customers by now offering two nasal naloxone products at different strengths &#8211; NARCAN</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Nasal Spray 4 mg and KLOXXADO</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Nasal Spray 8 mg &#8211; allows Emergent to do its part to help save lives from this devastating crisis.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Distributing both NARCAN</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Nasal Spray 4 mg and </font><font style="color:#2c2c29;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">KLOXXADO</font><font style="color:#2c2c29;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#2c2c29;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Nasal Spray 8 mg through Emergent&#8217;s expansive distribution networks </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">will provide federal and state leaders, community-based organizations, harm reduction groups, law enforcement and first responders with the flexibility to tailor their approach to opioid overdose reversal treatment for specific patients and communities. NARCAN</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Nasal Spray is widely available nationwide over the counter and will continue to be a trusted 4 mg naloxone standard of care in the community setting. With its 8 mg dosage, </font><font style="color:#2c2c29;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">KLOXXADO</font><font style="color:#2c2c29;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#2c2c29;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Nasal Spray </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">is a prescription option for those who choose to administer a higher dose of naloxone.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;In the midst of responding to an opioid overdose, having access to safe and effective naloxone treatment is paramount, and NARCAN</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Nasal Spray 4 mg and KLOXXADO</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Nasal Spray 8 mg are proven tools to help reverse the effects of an opioid overdose,&#8221; said Dr. Simon Lowry, chief medical officer, Emergent. &#8220;Broadening public awareness and expanding access to life-saving naloxone, the current standard of care for opioid overdose reversal, is critical for anyone who may be impacted by the opioid epidemic.&#8221;   </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the terms of the agreement, Hikma will continue to manufacture KLOXXADO</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Nasal Spray 8 mg to maintain distribution and availability. KLOXXADO</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Nasal Spray will soon be integrated into Emergent&#8217;s proprietary NARCANDirect&#8482; online distribution network where qualified direct purchasers, such as emergency medical services, law enforcement, fire departments, government agencies, schools&#47;universities, and community-based naloxone distribution programs, can purchase and ship bulk quantities. </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><img alt="imagea.jpg" src="imagea.jpg" style="height:28px;margin-bottom:5pt;vertical-align:text-bottom;width:251px"></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">About NARCAN</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> Nasal Spray</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">NARCAN</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Naloxone HCl Nasal Spray 4 mg is the first FDA-approved, over-the-counter (OTC) 4 mg naloxone product for the emergency treatment of opioid overdose. NARCAN</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Nasal Spray is not a substitute for emergency medical care. Repeat dosing may be necessary. Use as directed.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">KLOXXADO</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> (naloxone HCl) Nasal Spray 8 mg </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Contraindications </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Hypersensitivity to naloxone hydrochloride or to any of the other ingredients </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Warnings and Precautions </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Use KLOXXADO</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> right away if you suspect an opioid overdose emergency, even if you are not sure, because an opioid overdose emergency can cause severe injury or death. Signs and symptoms of an opioid overdose emergency may include&#58; Unusual sleepiness&#59; you are not able to awaken the person with a loud voice or by rubbing firmly on the middle of their chest (sternum). </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Breathing problems, including slow or shallow breathing in someone difficult to awaken or who looks like they are not breathing. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">The black circle in the center of the colored part of the eye (pupil) is very small (sometimes called &#34;pinpoint pupils&#34;) in someone difficult to awaken. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Family members, caregivers or other people who may have to use KLOXXADO&#174; in an opioid overdose emergency should know where KLOXXADO&#174; is stored and how to give KLOXXADO&#174; before an opioid overdose emergency happens. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Get emergency medical help right away after using the first dose of KLOXXADO&#174;. Rescue breathing or CPR (cardiopulmonary resuscitation) may be needed while waiting for emergency medical help. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">The signs and symptoms of an opioid overdose emergency can return after KLOXXADO&#174; is given. If this happens, give another dose after 2 to 3 minutes, using a new KLOXXADO&#174; device, alternating nostrils, and watch the person closely until emergency medical help arrives. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Do not use KLOXXADO&#174; if you are allergic to naloxone hydrochloride or any of the ingredients in KLOXXADO&#174;. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#212934;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">KLOXXADO&#174; can cause sudden and severe opioid withdrawal, the symptoms of which may include body aches, diarrhea, increased heart rate, fever, runny nose, sneezing, goosebumps, sweating, yawning, nausea or vomiting, nervousness, restlessness or irritability, shivering or trembling, stomach cramps, weakness and increased blood pressure. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#212934;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">In infants under 4 weeks old who have been receiving opioids regularly, sudden opioid withdrawal may be life-threatening if not treated the right way. Signs and symptoms include&#58; seizures, crying more than usual, and increased reflexes. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#212934;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Tell your doctor about all of your medical conditions before using KLOXXADO&#174;, including if you have heart problems, are pregnant or plan to become pregnant, are breastfeeding or plan to breastfeed. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#212934;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Tell your doctor about all of the medicines you take, including prescription and over-the-counter medicines, drugs, vitamins and herbal supplements. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Side Effects</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following serious side effect is discussed in the full Prescribing Information for KLOXXADO&#174;&#58; </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Sudden and Severe Opioid Withdrawal </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Symptoms of sudden and severe opioid withdrawal resulting from the use of KLOXXADO&#174; in someone regularly using opioids include&#58; body aches, diarrhea, increased heart rate, fever, runny nose, sneezing, goosebumps, sweating, yawning, nausea or vomiting, nervousness, restlessness or irritability, shivering or trembling, stomach cramps, weakness and increased blood pressure. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Infants may have seizures, cry more than normal and have increased reflexes. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Some people may become aggressive after abrupt reversal of opioid overdose. </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><img alt="imagea.jpg" src="imagea.jpg" style="height:28px;margin-bottom:5pt;vertical-align:text-bottom;width:251px"></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In two clinical studies, a total of 47 healthy adult volunteers were exposed to a single dose of KLOXXADO&#174;, one spray in one nostril. Side effects were reported in two subjects for each of the following&#58; abdominal pain, asthenia, dizziness, headache, nasal discomfort, and presyncope. </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These are not all of the possible side effects of KLOXXADO&#174;. Contact your doctor for medical advice about side effects.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Pregnancy, Infancy and Breastfeeding, Children </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Tell your doctor if you are pregnant or plan to become pregnant. If you are pregnant and opioid dependent, use of KLOXXADO&#174; may cause withdrawal symptoms in you and your unborn baby. A healthcare provider should monitor you and your unborn baby right away after you use KLOXXADO&#174;. </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There is no information regarding the presence of naloxone in human milk, the effects of naloxone on the breastfed infant or on milk production. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If the primary concern is an infant at risk of an overdose, consider whether other naloxone-containing products may be more appropriate. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">KLOXXADO&#174; nasal spray is safe and effective in children for known or suspected opioid overdose.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Dosage and Administration </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Do not attempt to prime or test-fire the device. Each KLOXXADO&#174; Nasal Spray contains only 1 dose of medicine and cannot be reused. Read the &#34;instructions for use&#34; at the end of the Prescribing Information and Medication Guide for detailed information about the right way to use KLOXXADO&#174; Nasal Spray. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Storage and Handling </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Store KLOXXADO&#174; at room temperature between 68&#176;F to 77&#176;F (20&#176;C to 25&#176;C). Do not expose to temperatures below 41&#176;F (5&#176;C) or above 104&#176;F (40&#176;C). Do not freeze KLOXXADO&#174;. Keep KLOXXADO&#174; in its box until ready to use. Protect from light. Replace KLOXXADO&#174; before the expiration date on the box. Keep KLOXXADO&#174; and all medicines out of the reach of children.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">For more information, please see the full Prescribing Information and Medication Guide, which you can find on our website at </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">www.kloxxado.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">To report an adverse event or product complaint, please contact us at </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">us.hikma&#64;primevigilance.com </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">or call 1-877-845-0689 or 1-800-962-8364. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Adverse events may also be reported to the FDA directly at 1-800-FDA-1088 or </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">www.fda.gov&#47;medwatch</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. </font></div><div><font><br></font></div><div><font style="color:#2c2c29;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Trademarks and logos are the property of their respective owners.</font></div><div><font><br></font></div><div><font style="color:#2c2c29;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">About&#8239;Emergent BioSolutions  </font></div><div><font style="color:#2c2c29;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">At Emergent, our mission is to protect and enhance life. For over 25 years, we&#8217;ve been at work defending people from things we hope will never happen&#8212;so we are prepared just in case they ever do. We provide solutions for complex and urgent public health threats through a portfolio of vaccines and therapeutics that we develop and manufacture for governments and consumers. We also offer a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers. To learn more about how we plan to protect or enhance 1 billion lives by 2030, visit our </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">website</font><font style="color:#2c2c29;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and follow us on </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">LinkedIn</font><font style="color:#2c2c29;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">X</font><font style="color:#2c2c29;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Instagram</font><font style="color:#2c2c29;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Apple Podcasts</font><font style="color:#2c2c29;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Spotify</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. </font></div><div><font><br></font></div><div><font style="color:#2c2c29;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Safe Harbor Statement</font><font style="color:#2c2c29;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </font></div><div><font style="color:#2c2c29;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are forward-looking statements. We generally identify forward-looking statements by using words like &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; &#8220;future,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;position,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. Forward-looking statements are based on our current intentions, beliefs and expectations regarding future events based on information that is currently available. We cannot guarantee that any forward-looking statements will be accurate. Readers should realize that if underlying assumptions prove </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><img alt="imagea.jpg" src="imagea.jpg" style="height:28px;margin-bottom:5pt;vertical-align:text-bottom;width:251px"></div></div><div><font style="color:#2c2c29;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">inaccurate or if known or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Readers are, therefore, cautioned not to place undue reliance on any forward-looking statements. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake any obligation to update any forward-looking statement to reflect new information, events or circumstances.</font></div><div><font><br></font></div><div><font style="color:#2c2c29;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There are a number of important factors that could cause the company&#8217;s actual results to differ materially from those indicated by any forward-looking statements. Readers should consider this cautionary statement, as well as the risk factors and other disclosures included in our periodic reports filed with the U.S. Securities and Exchange Commission, when evaluating our forward-looking statements.</font></div><div><font><br></font></div><div><font style="color:#2c2c29;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Investor Contact&#58; </font></div><div><font style="color:#2c2c29;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Richard S. Lindahl </font></div><div><font style="color:#2c2c29;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Executive Vice President, CFO </font></div><div><font style="color:#b14a32;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">lindahlr&#64;ebsi.com</font></div><div><font><br></font></div><div><font style="color:#2c2c29;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Media Contact&#58; </font></div><div><font style="color:#2c2c29;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Assal Hellmer </font></div><div><font style="color:#2c2c29;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Vice President, Communications </font></div><div><font style="color:#b14a32;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">mediarelations&#64;ebsi.com</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:32.532%"><tr><td style="width:1.0%"></td><td style="width:37.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:59.984%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">1 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">KLOXXADO</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (Naloxone HCl) Nasal Spray &#91;</font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">prescribing information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#93;. Columbus, OH&#58; Hikma Specialty USA, Inc.&#59; 2021</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> NARCAN</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Nasal Spray &#91;</font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">drug facts label</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#93;. Plymouth Meeting, PA&#58; Emergent Devices&#59; 2023 </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">3 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Centers for Disease Control and Prevention. Provisional Drug Overdose Death Counts. Updated May 15, 2024. </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">https&#58;&#47;&#47;www.cdc.gov&#47;nchs&#47;nvss&#47;vsrr&#47;drug-overdose-data.htm</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  </font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>ebs-20250114.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:7308415f-beb6-4e39-b0ef-bdca129f68fa,g:bc0f4012-f9b6-42b6-984a-7db61b60311b-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ebs="http://emergentbiosolutions.com/20250114" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://emergentbiosolutions.com/20250114">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ebs-20250114_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ebs-20250114_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPageCoverPage" roleURI="http://emergentbiosolutions.com/role/CoverPageCoverPage">
        <link:definition>0000001 - Document - Cover Page Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>ebs-20250114_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:7308415f-beb6-4e39-b0ef-bdca129f68fa,g:bc0f4012-f9b6-42b6-984a-7db61b60311b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SecurityExchangeName_5848174f-8385-4519-9638-fd267619e331_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_b4e7cd3c-b0a3-4b0f-9260-d1dde503743d_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_a8c0884e-6f1c-4725-b56e-9272fca58abb_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_1bc871f7-7b7e-49b3-a04c-3cb0a8993214_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_2b9c0be8-31d2-4513-b874-b4d585670354_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_58013aee-eb0d-4555-b960-f6c39bd374a7_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_6fcf6812-7ad6-45c8-b1c3-b6727c5c5b50_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_d98225c9-9b5f-482f-a806-2237843eef5c_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_8da236db-4c94-48d6-8de4-d643b44e653a_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_0b7ea227-ec60-4550-9a8d-aa1d2e9f1f8d_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_a8f0c7f3-a205-4c03-8f3a-2421967cafa8_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_c84e64af-854d-4e95-877f-fc26d0059356_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_aef0ff99-79b1-4ab4-81d1-ca74568d9ffd_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_d06c24bd-3b27-41ca-80fa-297f6f456c71_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_4ef45bdd-57b0-410d-a327-1d98d5de2750_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_db26176f-0c08-405b-9f55-db7b3fbc6eea_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_3ff37689-3e31-4f07-a9f2-8c2c4f069c22_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_ed907b46-097a-4fb1-9322-54091ab58f55_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_604554c3-36d1-45d0-957f-18b977f365c0_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_adc281cb-9fa7-447f-b1a2-8c3b832aeee0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_12c3ff72-1c64-42d6-b951-b3ed9499cbe1_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_ffc8a6b0-150c-45ab-ba86-46c0845eeaaf_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_8eee8944-40d6-49b3-b0b5-b19f131e0bda_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_1907f965-f935-4f90-ad16-09bd805b7217_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>ebs-20250114_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:7308415f-beb6-4e39-b0ef-bdca129f68fa,g:bc0f4012-f9b6-42b6-984a-7db61b60311b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CoverPageCoverPage" xlink:type="simple" xlink:href="ebs-20250114.xsd#CoverPageCoverPage"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/CoverPageCoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_a182ec61-e0c5-4fd2-a4f0-0cd7010558c5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_330bdc24-2db8-4e1b-a6f5-c7c55e8c830f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a182ec61-e0c5-4fd2-a4f0-0cd7010558c5" xlink:to="loc_dei_DocumentType_330bdc24-2db8-4e1b-a6f5-c7c55e8c830f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_5071e842-3bb9-4df7-a0da-6bfc8483296d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a182ec61-e0c5-4fd2-a4f0-0cd7010558c5" xlink:to="loc_dei_DocumentPeriodEndDate_5071e842-3bb9-4df7-a0da-6bfc8483296d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_f8d1af39-b2fd-4d5c-91a7-3fc004a6063c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a182ec61-e0c5-4fd2-a4f0-0cd7010558c5" xlink:to="loc_dei_EntityRegistrantName_f8d1af39-b2fd-4d5c-91a7-3fc004a6063c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_54493c44-0d22-40b0-8959-1bff3aef7f7e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a182ec61-e0c5-4fd2-a4f0-0cd7010558c5" xlink:to="loc_dei_EntityIncorporationStateCountryCode_54493c44-0d22-40b0-8959-1bff3aef7f7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_417b8a1e-6950-4540-87be-d6a68ea885bb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a182ec61-e0c5-4fd2-a4f0-0cd7010558c5" xlink:to="loc_dei_EntityFileNumber_417b8a1e-6950-4540-87be-d6a68ea885bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_d6eb92d7-3bba-4b69-bfcd-cf1773c959f9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a182ec61-e0c5-4fd2-a4f0-0cd7010558c5" xlink:to="loc_dei_EntityTaxIdentificationNumber_d6eb92d7-3bba-4b69-bfcd-cf1773c959f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_101eacce-25f3-4a51-a837-de0227ae1279" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a182ec61-e0c5-4fd2-a4f0-0cd7010558c5" xlink:to="loc_dei_EntityAddressAddressLine1_101eacce-25f3-4a51-a837-de0227ae1279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_38cdd872-722f-47aa-bfb9-632ae32c84f4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a182ec61-e0c5-4fd2-a4f0-0cd7010558c5" xlink:to="loc_dei_EntityAddressAddressLine2_38cdd872-722f-47aa-bfb9-632ae32c84f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_b6039e29-5b6d-4046-afbb-bff71cf7e71e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a182ec61-e0c5-4fd2-a4f0-0cd7010558c5" xlink:to="loc_dei_EntityAddressCityOrTown_b6039e29-5b6d-4046-afbb-bff71cf7e71e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_a4770a73-604d-4b33-a364-1c1af5f0d570" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a182ec61-e0c5-4fd2-a4f0-0cd7010558c5" xlink:to="loc_dei_EntityAddressStateOrProvince_a4770a73-604d-4b33-a364-1c1af5f0d570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_c47b912c-4767-4785-b2e9-56d6ad34d870" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a182ec61-e0c5-4fd2-a4f0-0cd7010558c5" xlink:to="loc_dei_EntityAddressPostalZipCode_c47b912c-4767-4785-b2e9-56d6ad34d870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_ac578fdf-65b4-4c09-9c27-6e0df67c33b0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a182ec61-e0c5-4fd2-a4f0-0cd7010558c5" xlink:to="loc_dei_CityAreaCode_ac578fdf-65b4-4c09-9c27-6e0df67c33b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_8cb230b1-5580-40f6-982f-6cc865ec16e7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a182ec61-e0c5-4fd2-a4f0-0cd7010558c5" xlink:to="loc_dei_LocalPhoneNumber_8cb230b1-5580-40f6-982f-6cc865ec16e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_a0582ff9-3848-4254-8034-e3953a6d9db3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a182ec61-e0c5-4fd2-a4f0-0cd7010558c5" xlink:to="loc_dei_WrittenCommunications_a0582ff9-3848-4254-8034-e3953a6d9db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_59583ce9-802d-4d72-bb64-7fa11babc2af" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a182ec61-e0c5-4fd2-a4f0-0cd7010558c5" xlink:to="loc_dei_SolicitingMaterial_59583ce9-802d-4d72-bb64-7fa11babc2af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_741660d8-3215-43dc-8011-1b07c265ca18" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a182ec61-e0c5-4fd2-a4f0-0cd7010558c5" xlink:to="loc_dei_PreCommencementTenderOffer_741660d8-3215-43dc-8011-1b07c265ca18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_d94e7585-e328-4f04-bd8e-1d1b73075b07" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a182ec61-e0c5-4fd2-a4f0-0cd7010558c5" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_d94e7585-e328-4f04-bd8e-1d1b73075b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_10e8142e-a520-4321-90e4-b485f3596215" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a182ec61-e0c5-4fd2-a4f0-0cd7010558c5" xlink:to="loc_dei_EntityEmergingGrowthCompany_10e8142e-a520-4321-90e4-b485f3596215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_61226c08-54ee-4369-a9de-b1ed0e09064a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a182ec61-e0c5-4fd2-a4f0-0cd7010558c5" xlink:to="loc_dei_Security12bTitle_61226c08-54ee-4369-a9de-b1ed0e09064a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_c3bab818-94d2-49a3-b63f-647a109a6807" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a182ec61-e0c5-4fd2-a4f0-0cd7010558c5" xlink:to="loc_dei_TradingSymbol_c3bab818-94d2-49a3-b63f-647a109a6807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_dcd6aa3c-d949-4e9f-8736-733d022a67d1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a182ec61-e0c5-4fd2-a4f0-0cd7010558c5" xlink:to="loc_dei_SecurityExchangeName_dcd6aa3c-d949-4e9f-8736-733d022a67d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_ca9da25f-541c-40c9-99dc-0925db29ca43" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a182ec61-e0c5-4fd2-a4f0-0cd7010558c5" xlink:to="loc_dei_EntityCentralIndexKey_ca9da25f-541c-40c9-99dc-0925db29ca43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_a242205a-2c17-4fde-a306-c2077ce417e6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a182ec61-e0c5-4fd2-a4f0-0cd7010558c5" xlink:to="loc_dei_AmendmentFlag_a242205a-2c17-4fde-a306-c2077ce417e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>imagea.jpg
<TEXT>
begin 644 imagea.jpg
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MUZY=0U:M7*G?@TMGS\B6;X;+U#H/J;>_7\R2JYCOS AMS<"N<N'D[QHGD&H
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M/Z.R++YFAHS,9M:O*+NFC\_P-0/41<4*Y?3&#KSEB906-ZR0_=V>_93#+V2
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MS9 Y36K(Q,?S91$S'&?Q-6-#^MF#>V,>E5G<L$+&OKA$PU4 $(N0V;@L'+.
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3-((HALK-I     !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm44843778687008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page Cover Page<br></strong></div></th>
<th class="th"><div>Jan. 14, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan. 14,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EMERGENT BIOSOLUTIONS INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">14-1902018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">300 Professional Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Gaithersburg<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20879<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">631-3200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EBS<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001367644<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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ML0(  .(,   -    >&PO<W1Y;&5S+GAM;-U7;6O;,!#^*T(_8&YB:N*1&+9
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M8*<D3?,\C@ 69Y"F& *G$4<P!L !0])T> \^>Q\ETWLJ.?]74_P$4$L#!!0
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MU\7!ZQ^4ZD2HN7/08&<B+EA0BJN$7/D=<.I[.T!*1D.QD8E>I6.5Z*U .EK
M>MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ
M!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO.
M\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( *9!+EH'04UB@0   +$
M   0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%
M  @ ID$N6I,[:DCM    *P(  !$              ( !KP   &1O8U!R;W!S
M+V-O<F4N>&UL4$L! A0#%     @ ID$N6IE<G",0!@  G"<  !,
M     ( !RP$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "F02Y:
MWQXO4U0$  "6$   &               @($,"   >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&UL4$L! A0#%     @ ID$N6I^@&_"Q @  X@P   T
M     ( !E@P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " "F02Y:EXJ[',
M   3 @  "P              @ %R#P  7W)E;',O+G)E;'-02P$"% ,4
M" "F02Y:Y6B*[#D!   R @  #P              @ %;$   >&PO=V]R:V)O
M;VLN>&UL4$L! A0#%     @ ID$N6B0>FZ*M    ^ $  !H
M ( !P1$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @
MID$N6F60>9(9 0  SP,  !,              ( !IA(  %M#;VYT96YT7U1Y
><&5S72YX;6Q02P4&      D "0 ^ @  \!,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ebs-20250114.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/CoverPageCoverPage</Role>
      <ShortName>Cover Page Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="ebs-20250114.htm">ebs-20250114.htm</File>
    <File>ebs-20250114.xsd</File>
    <File>ebs-20250114_lab.xml</File>
    <File>ebs-20250114_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ebs-20250114.htm": {
   "nsprefix": "ebs",
   "nsuri": "http://emergentbiosolutions.com/20250114",
   "dts": {
    "inline": {
     "local": [
      "ebs-20250114.htm"
     ]
    },
    "schema": {
     "local": [
      "ebs-20250114.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "ebs-20250114_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ebs-20250114_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "report": {
    "R1": {
     "role": "http://emergentbiosolutions.com/role/CoverPageCoverPage",
     "longName": "0000001 - Document - Cover Page Cover Page",
     "shortName": "Cover Page Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250114.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ebs-20250114.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPageCoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001367644-25-000010-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001367644-25-000010-xbrl.zip
M4$L#!!0    ( *9!+EK\.\]=O@\  +-S   0    96)S+3(P,C4P,3$T+FAT
M;>T=[W?:./+[_A4Z]NZ:O!<;V_PF"?LHH5VN+<F#]+9W7_;)M@!=C.V3Y03N
MK[\9V280((&4+B2;?D@QDD>CF='\TDB<_3(9>^26B8@'_OD[4S?>$>8[@<O]
MX?F[9K_5Z;S[I?'3V5\T[=O[WF=R$3CQF/F2M 2CDKGDCLL1D2-&?@O$#;^E
MY,JC<A"(L:8EK[6"<"KX<"2)95BEK%O6*NJ5@E$MFJ6!9C.[K!59H:;9!H-'
MUZ&F51N4JP-Z,JS;CC$H&J:E#6K8S8(_M6J1:A77+IMVV2B8IGWBUAW;= H5
MTS4JA4*1%1DU!C67%5R#5:O5@E-0XXXDS!GF[4?UB<?]F_/<2,JPGL_?W=WI
M=P4]$,.\6:O5\JHUEW1=WPG!I9WJ+N.SCA-;>'K$''T8W.:A(0\$*&0=)Q%?
M!=$R##/_[<OGOC-B8ZIQ/Y+4=UCV%I_(A;?4$/@>]P%5ABS*2T']"#E )? 4
M!S4TP]),:PZ(!F@M ,K0? R.6=*,JE8P,SA+I)MA [,HY+'9IM$,=VSEC_1?
MGNNZSF9A#D_5O>Y1D-<<\[6O_5SC;,2HVS@;,TD)0M#8?V-^>YYK!;X$V=6N
MIR&,XB1/YSG))C*OF)AO_/333V>22X\UF!UI*+&&:1;/\LEW9_D$LAVXT\:9
MRV]))*<>.\^Y/ H].JW[@<]@?#ZI8T<FDH_<=9FO/D)[%]:/X$XR_$3VV. \
MYVA 5)^.$1+C];8/PTU;@)R@7L=WV>03F^8(=\]S \VR<@T#I*10KI2+@-D"
MU"T&:<(R=G$I?_#H< :\D&L,J!>Q);CYQ8D(-F "% 6+5I ?.5^/E 3#R$2M
MHKH$HI_G(CX./62Q^FXD$+%Y2NN3R 4VJ.'NQTB'C()8J"<E2O5T<@IUG%SV
M/5/DRYZXB\\#S@11*+&5<M_J?%HDZ\.7&]E7B]!#H$[@9D\@P$)>@%YLX'PT
MP]3,&:C[MAF:[IJN64OVG V27YAW1J095?)S8I<'X4PD%*G#GU*+OR/U[M])
MI7K,?6W$4'?7BY9>*87R](Z[<E0W#>-O.=6U<1:%%$3"%LBTY',"9PD:ZAP-
M\!;4D?4H'H^IF)[B1#3J\:%?=X"R3 !826V/96_9@8 ):4[@>32,6#W[<)HM
MN403:.JE4X Y!*3M0,I@7$>$P;1)[E O'42-ES2G<ZG5]&JIC-.10#?I9@.G
M,]5AIOD5WU?UFK&ZR=#-U:^\@5H+*J]H+[+&5.@*H<RI=X#I*%KG.3"?BW*1
M<MH,)8D"C[OD9UC$IVFC#,*'+2%UT;6I&P0:4HS>H.\!NN)X7JW:%;IBE5I
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ME3>J/H^JUW322=/ZCA+Q11)7<@VSJ)DUPS+,ZJ,T?J%*8LE(*BH>J86.(5(
M49$@_X&@*'*Y"J!>OV2MH4DK&(]YA%OC!-<B223E^$]+CTZO3]KCT NF3+S>
MI0"N+Y\W@3^ W[OM]C+(NJAT23?0CY=E:(\[ L\))O:1X=HB,9(8O*;K"A9%
MZ7^? :"9&;MJKE$P#'(E@@%3>HYZY$+PVR67[>2I\&DNP#F45. SZ=2"CY?B
M.KB;N;*U7.,CY6@6(SL6PR7:/)<CRN1>"J#^+5>%+QNZUJ:1:WRA8NI1WUW.
M,CP/EZL !O/^S</$R4\',G,-RZA6:H><RUBW2G[($MTPD9(2%;,HH0#>\A 6
M%ILP)Y:PN.!K4(,L.D$[X\6HP\G_> B\<MF+3Z<<B@ <;;X0<,4W!:,+HF^!
MZ!>-AX)_O,7Z^AR Y;T:!?Z#(,XLY!KE D1QEK$$_Y 6UAK9OD^%_OWGJF56
M3B,BF<="G"CQU4SG!1OB?_I,R5Y55G2 DM;--P\(QS5<^P"F!<*Z)+<KE*6!
M1YKH*>#7@"1[7RZ)T!81CT;9;LR+54G[0:8U8LZ-VEJD(=ANT/\86-O!A-C,
M"^Z0U-B(#$GPKFJ?R(![N%AX!"M',M\%/L@ 6#&./4E]%L21-R41>,[18*I>
M3U\(;*!^XE"G^YES6?L8X "/_6G6-@@\P #?0Z>"H\,7D:,?;"D5Q#H'[X([
M&Y O8FR?IIM\9#X38*T[/E Q5OD/TM0M/>'><?U I&RS38VL3,M2E70;XMD$
MB?7(5Y^CUB9?^M^'Z.;V\C?!)<@^)EUB/PT3HV6GV X"SZ8@R!+6U,RF%I$D
MM4JQ>+HN9[<_+B5_23H_(,'\!$DX5['0BSV6]"Y:I73]/BA2P-J$([-"6A]Z
MQ"H8.G1<KZ!?HACT U 4,%=_^ 44)R*QJ0R4=B4#O\'@Z+Q$WZE+]BEZ]V0D
MXY2.:T3-+%)P=^>D;:$.9B9K14-/>KXN<;L2##4.GC-096YH?,7E8(#^^F9B
M5WX3N[GZ*\$T9XZ>FVD[L^AJUI&=5F9M)(G)"Z]:%CM1%#/Q#(FLO$GD=TMD
M@6G%(V<+B4Q?V%@B$?NYVI/M)'2WIN+>NTBB!R8@_@B7*RF)B6LNBR:  LO>
M\,%6U=2*NFG4MJVJ <9:E>)NCL'4]')Y1Q4L9;WR!*@G=N12<GML(!\<U3 >
M.\=AS!WE6+'KA. .:L_I&H]M)F6FSH@X'HVB#3;S_BS$$51EZ/K3L1UX1]$F
M^YP;D48D@[Q>RG73"DDE52RS"* ?[T8<OKE7HMMLDC]VLFJ.>J]=*K<(%!.S
M-34M6ZWSF?M3S370C0)^]&7@W)R0OQJZ89@DI(+<4B]F),33P*/GE::]\6E+
M/J5Z)E$S,R;5<HWV^_Z^Z/_J5=3VRRCS;),"]X>!!FJYQ5UHRP!%",C^*Q W
MR4*;.<=/E\VMK?-8].QJBSYR;6\N<L=W,6!@Q)X21R7X :T;T/=,5<L]2+SS
MB "*$&T@YD,R%,&='&'<$6(RGD;$90,8 DOID_@"XPY2-$ID^5#2_5FD CG"
MWI53E?;+.G-5B1]B)3YN["A(H!$U:P6L50><9D QAKE_;PZLOGY3<HE;>V)/
M>PVIY_.O\W^WC$?WE0](*C2RR7U4<VLE4]LP%6"93Z8"#I:IG<$CJPBWF%<N
M2;ZT#3:"!<<\B&!AP?F!BF?CB*E>0/=TLPTON^$JQDUNVT#RJK&\*0ZNKCE"
MB?)A;M BV"V/X#U8QM1W4#JHXV"5/';&>VQ<*MPHV69S5P?369[AB,XBZOGU
MJ9-MLR:[E=*9U&PJ)<N*^NTBCS\=J+>+//YLT!]WYQY<'Q0&B9*M"^91+(5;
MNE#H'CV%EW'_"K4!C5@NO_+4'43)W]%,*$,Z9)HM&+W1Z  <G#KU[N@TPLG\
ML,N/EK7E7/#PGSB2?##=4_E21[(QJ>H0'U\J7[:-![$C?0O%OSR5Y"NPT "J
M7BCOS86X],G#(]8G1/E3N!'PG@=]%"FU#=#Q'1U]X:IE&:=9%_5HGAZ#1Q_%
M8,8I6'2LZP3Q911\".K[8/0=5>?F$SH4+-EB4.["K_QF3,G5B(*?YK!86:\'
MXZ@N]X-D":09AH$MJ0H4U :&4(Z&"EVQ3DBY#&#NT:]1I<08=;BD17WJ4G0T
M9M!5D=ZGSY??OC4O+G_(7DQ9+VW D!7K'U6,5M!76'B\.Q !J"J*2O$'U=QO
MN(%UU*5>,,$*QU];WC'IT@@XT0\%!4<4T*F2\1#\]K0+1=YMO8#VOUJ^SG:Y
M0"N.H\PKG8GU22K2=]SS5-C"_9BAH,'(\8 Z,A;L3<R^1\SFY$K)U$FJ$!3%
M;::* X="7;P*'P,RKZ?4(D\*#IE$C==M]EK-[@47$&] AV+5.B4N!D7<5CH/
M8AEY%XB;%RBI31"_<%;6N*B3>83%D:BL,>$QXC:7!&(#4RE'56"9G>V"/F#P
M&&A2""%GMTU^G^7[XXVX:65&O(9&_,,L(E4V ==M8A=26FQCV??$77+D'I/L
MWV%5IV9$W*>6^&X!_6/C<O"7=2/QF;<*S"V]7-O-=KFIU\S*3B!5+=VH;10!
M/^/,YA[W$%:?K,^T9S?0-]B7>>&'5E>3X()%CN#ATBGXW7(9O),];1.A8=P=
M;W>Y>Y;0Y+'Z^L'@AQ$F0<YE3GH$O*X*P!(W\8QFN"S<:,R2Q7*Z=P1)<JNV
M<HI2G^AWO%H;@U]]),>J(F[!7U*A+;A CP3&X"V>Y>DKF/M].N!US$<E-5['
M5$JO8QJZFL9B.G#W)F/,7==C>[(:IE'\0QR"1SVB?1R]4K-O!8 2N:)#!KH1
M'!:03SS4?4$E3:Z).6)CF[EN^NLH::*NH]QHHGY%Q4VOCSS6U\G)6T+]>Q+J
M>ST.W.]\[#:OO_8>N3!\ZQ0ZWFJYIV!\_D+=9&/]OS$7:5YALQ*3DU4[\F[L
M38E#8]Q%5^4FR6%C',:&X!0H 0U!<M6DS4;4&Z"+@H"4,DX[8/XFQDR8 D=C
M.0H$3,Y],D9>49BN$NLOY+;'$H2;U<?O,-RXF%PO%7<3'<.RKE4>O]5Q0R.X
MTF24-S$9BHD'%4(^=D/L3B+*?4YYM85\<#CY:1?A;5:'-*O7)(IX,;=;7]H%
M?FU<?#^MO[8IY:,\Z7&\9=HE?9U\!E>(CKSG".IN;MM[;G+K\"B+%=YULHJX
MZ'BKLQ30W)Y=5_5/[C""22/U<V@GI#7B;#"WT:1>NU1W6@FUU70-L4 4B]67
M1#ZL#:L]4ASV@Z]5?"FA5C[YP4'U(X6-_P-02P,$%     @ ID$N6J5A(#%P
M @  . <  !    !E8G,M,C R-3 Q,30N>'-DS51=;]L@%'W/KV!^'OZ(TS2.
MFE1:JTJ3LJWJ6JUO$[:O'50,'N F_?<#8I:D:3IE3_.#!?>><S\.%RXNUPU#
MSR 5%7P6)&$<(."%*"FO9\'#_0V>!)?SP>#B \:/G^X6Z%H470-<HRL)1$.)
M5E0OD5X"^B'D$WTFZ)8170G98#QWM"O1ODA:+S4:QL,S#_->.3U/X\DH.:MP
M#OD8CR#-<!Z#V98%2899-9Y4Y&,]S8NX&L7)$%>9A0W-+YN,"#XO\W&2C^,T
M27(7=*VFJEA"0Y!IC:OI6LV"I=;M-(I6JU6X2D,AZV@8QTGT^&7QW4&#'LLH
M?]I#KW/)/#Z-K#LG"CP<\FUL:$#61IB<"B58IXV>*BQ$$]FNXR09!8AH+6G>
M:;@Q\EQ#13JF9T''?W6$T8I":;1G8-7= ^RX-3$Y]%?2@&I) 2<DGP\0LM+0
MIA52(WX0XK!;RI4FO##=;O1<B()H-R9'*7:'/0];$S8GEB;A6I5!] \U;!4_
MK0;/.[T&%TQ!$=;B.2J!6@G3M].K8W"[P':QGY-P+K3C6TMO:UO**[$Q&),M
M?.JKOX/*#_'!9/9SG&19%CFO&4I')K*0@L'[X*B5H@6I*:C=J78!EA*J66!F
M&_OI^=E*"$TA'G$0?_\$K-LD &4FTK6[V/;C0^B7UH10YA@8;!3ZC]MG)#^U
M?4,!=F+?EGAO_(B6L^!*F%?YEM3P9Q$@"WBX^_SW:^]*>"."S^<SEE!13MU$
MQNY+$-X^\1@Y)K+4G>5%])K[*FJGH/S&YV[]>@QZ<@]YAU@05G3L=-ZVK*.T
MWNCE[B]CM'\;-_N=&^L,FV=@/O@-4$L#!!0    ( *9!+EJT5RP_8PH  !19
M   4    96)S+3(P,C4P,3$T7VQA8BYX;6S-G%UOVS@6AN_[*[39FUU@6%,D
M)9%%VT$WTRZ*S;1!DV(&NU@8_$R$VE(@*TWR[Y>2[<2*)5ND;&5O$G_0YSWO
ML1Z3AY+]]M?[^2SXJ8M%FF?O3L+7\"30F<Q5FEV]._E^^0G0DU_?OWKU]B\
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M?#@LT93:]2IEQ$ZBL/JZ6O7K!P**R*YIF0EQJ*%0O??C.U5>$LO+NWPXEF@
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M<C3UN=3^[XG,54J'> E4ZLH<AVFE+?XIL\SPXB=*%8(4"CUN:'%%3(^G.^Q
MU(R7,F4Y4-8?TNWKE*<_KI_ACL]^???FX_GK3Q]_;(F?XTY+_%.F'='=:7FK
MXNF//[U__4;\\N;S^>>SCV^>"6:^[I%8C5S/TJ@CGO[R?^=OGCS>W:>K7I\_
MH\5+2=%'9,<4-B;&+D:R$+H0(^D$0VXZHU-:1YD*.<R58MN'_K;]@JB$V+\"
MPM$,".<>"--I+/RGSGF'B>1$IC*6N'DEK NBXR;@^4&)XGO#'/.:JPE!6E@N
MEM'U)9()PB\O\6R6Y21O8S&P.2_2"ID+%KU([205=(TK7:8BV+L+TII>Y01Q
M-,ESA]/]*0D0E^E<%C:?8MV?/-[9.Z)'P(3+:82IRL>6Y(R;T@T)R0,@)4?3
MWOE>5KQ[#XO]ZXB6S>G+]E3)O,&*Q':D3[V.!).1 %;ID)845NJB4DXT3S0K
MT]P6M* MXO*1) '0\G?+,73SF#0I+>1(F0PBFRXG.5!&:DE5QT0K(^<%3^\(
M-*6A5GA4RAC\2@?I5J(F1L)0WC;IT_?%A!^*D9 L.'11R96&RIG1;M ]M<[Q
M@\60)![:$7]>;=S1NOTZ(A%*TI2FM:]4*H;@+BP2&5NUA!RPIT@.H7:#LO3S
MK#*Z+-$1+3PM$4G][KZ8T-+.)/Q YW2+C/Y=:A;51 4#(X=NI+-JYEL;&^X/
MVW MFF8=C2 J:9UH?*P@"?S0@AA(.!H]D3]+SL& ^,A!6DH/:XL1NP;3!K:M
MQ>MW(^.>/#[H'O7HY_9]+,4Q33'T!?V3V;SPSB#,]@F#$L=ZZU0[DA1PP9%B
ML89EP@<L3<HV=V13XH[$\7UIF?15CD6Z0H0UP4JL6 ;1FAM)W,42M\)6GE_!
M=(F26.)!:7 #/J+!IM_-.F_?BRZ#4)3XOQC+7"NR$VEE!C(BS. \2(FPJ&PT
M,N<5(V9%GF:"KP='7EV5Q*,DYH9 $$0K.B6Z(%W!J^3G@P2O3C(9,9Q94HC0
M4[F"LL2%*6L3F"($5 HU9/A2&R[$Z$2*KJ&D*LTD&!_'#9L(PF LM9%]HU;:
M.0]89;%)NG5$BT3?23.((1/-\$?5<UU8^E:@#47*&Q"!KB[8@3@(^,%8YPV%
M!7[#LM-C$C8C.\M+0M1+?QJ\)%:Q]AH>#YH@B)(./6PH1GB6#?J3;,X"'\)C
M9*$<%&>+9EO)V6T\3? 3L-^ AC+4D.0!3Z1#.:POE?'8TLO#M9:>2A VU\Q%
M]-WR0HVLB2&+FEJ\)<H4!R.;JT#)$$@"R\^2!BJEL!:0.9!7F2] H)C);8)[
M)V172?YZ8+':-*=IE_& 9%.+%XO$DI,TQ_^T2GR0F?3.1PV7AO_0D58#,M54
M5#)#V,% 1RIOU9/?$6'1?R9KO5I.^%%X0C'"RO?BGU>[7P@DDH6 !RHV_XN)
M#51>$WU (71G(6*-"Q53LH>IKA:L&Y!R*T<S+\C&9+[%[+%]7%&?-,9.9A:3
M9T.&TYG,BYH!&_91@"2LEL;$BI(9AR2$TZX3V/+!ROC3RB6+,?=)N&W8[T^P
MWX.,[OSY /,ZU^N.YFF9X<DXL^5PM(P[.)#!,+".5P!XI*H \'#W$'#A^(KW
MJ1"Z4 0KI D^'L(EPA &8.Q2Q3^F[3X;+38?DF7R109_"[RLWG_#'S2D[\_H
ML)$30CR,EY,**'C#!OX[RRBFPEKT>J,N]2RD4Q"V]9Y#G7MGHB0DO@+M>4N9
MQCUS*\)T@S-1$PA9P!6S0$YG(Y#^.(%K+%BLS'3.^,#'3*K8/B]F%=O'G#.1
MP=C2::FP@GU8945>LC=W9\Z'3'27QH#]! H!GBOD6Q.@<*HH&-9_!N% ?3+3
M$2G(H6IM!.7W(2C73\8(2<QG3'AW<8A/0)),1I8,&8M?86['9':2G 85BQ$]
MB7YA@=.(*W9N ;_N'YH%2^S,LU:B8\>NBR"4@SM>ILMQF)&/IL]<$DX.E#=L
MV47I/1R!E6?B6#/$E0ED@K>#-Y)W8XFMWQ(+?B$X2PIKC6LX/58[VY=98,X9
M<IIWQ+E.2(;\9"?YM!6\( G[E,PU/I#7!&9B[[W/RKXAD+*0Z\ 9+_.LUDQG
MJ7BLY75CF0>'QX+NA&2["BVUP)6ULPE7RG0*MH403&C&^I57TT=<5X2,*A-4
MB(?K:?P$D.E=APJ.^N"\JX.;K9 HL(11$IF6\!:7-(\;CKNU*82)U"GG<<S9
M/.S+]@B2$7]G,\FWF60F6V=I0L&NA+B'.5<,<#[-DOU)LB]#*$3FTZ"!3W5.
MPHXNV-GO'0F;<HAIE7&*F#!QPK]+FH:!IC?$?">)KSP:T9S 2.10"9)ZZD2/
M2A+2^3&)PF63L 5[$&YKN, 2GWDWA*Q*O<&(QVC<YX#+D,"SLW=$=@!D&!MQ
MK3FKKC)/:PPR]RD<69 )S%F2[-7(O;F+8':_-!?X0A("WCZ\519XLR9BF;*N
MJI(()0U;LUMDWR&O:OF6*P?1_#G*9^F(0]7N$Q:[:,L!"<%#:29RZA[]A8HY
M[H;]5M<3'/=M6:P#OZZS]N*.YJHIJNX5!6S,C1MJEEFRW[+MH5TC,^'MZ7&[
MRO!K+9=T/'W_Z\FS!==.E:7UE7S !<"Z\=+=SDN76E*?I)+[CK09\N(Q[<N:
M&79"1WQ4&7+&:+YA703TGRJ8'H05.N(3U*0+.E_%M_%ZK$?BK 5$_A4D\]6)
MO1ZXW^LJ<K85F0Q5:H9;UW!6L]:[:0;O0,JY/B$Z44_?:!KG-AK1^]G_G7O7
MV;0R-'U2!W%53@S'48@'RSN?90Z/A*N2W")97C'YFTJ7&U2Z0&9N;-H;*B]?
MR"XGT%T#,;5E50VPP@<WTV(MG_@4[H#'"UK/E;EJD0(C^F7K[IKB+]B!_C('
MMQA,Z-]+,HZ)C3F3"NX]I*6QB3A-,K)$KG ,-E4K/B*-3!DK7P7S*2U="2O8
M*)4AA<SY],+FH#F0!M$QD1?*^^4A=,AJ#2GLQI:Q&%L=L9!!"439[T-;(P'5
M3*L\M43'L5%!^NA<1"-%:.TIHAAIF3Q;8=-NF/D&S/P:"'44:@UHJ>!$\&O,
M%6D&"6ID<8\XQT?TZZMU*IQ-E'=%P!U<FJ*QS'0/W*W&V@LGC+Y@#_2T)HKZ
M.9MEN]VR(<&T;V1T(2*=1V863>84[TI'\[A4[-.PJNS.J1)/LS+3!(X(31.7
M3X5+:'F)EVA!"YTH1Z+#&+KOR>/MG2-B[,SJ%!XQNLGQL6=?6?_-LMYN6=_R
MX\F&0<(]N_.J+%MPE(=<F;(H JZB&5P>0Q-?-K1RJ ?7Z?7RW(UL:6*N4PM>
MT,4'(%N6*0AZ8D27T8LPGL4+^XJ,L*^HI!%9U00U-Z1Q.]+X414KK%P?Y)MA
M#':$AK8Z,Y]&%=R?7S58QRXJ54.J$Y&=?/@HGA+=Q=IFI4EL"I]ZK@BU1+I@
MH^79S(Y6,4K11AKT*#4G1*ZVQC'.S<K?7M:[/X[6  %S591Y&JABF;G!RB2K
MSP8^%S=P:,NSN$R]O/&%!_R$'OA_FZ!86A:(4'@ZDT0(D\6GQPIQD18<Z 30
M?'YO:A&S,"&T,9%%-&KBP<C0FTCZE6FAS56T+O,<&<0;6KH=+9U:QE^KE,7,
MUH#RSX<ZNMX=T/ %-+T I'06Q<Q?:*EZW=X!X9]U+-7"^C0LNC*F^?'"P!MW
M00C H(IST@/&IT\T184OR6Q8< +-TH2$&=4B"$=\-5*R55=GD;I70(V(NK;$
M .]ID666IBA:0<:4(^G_A0:-L"8=Z)<)$F/=1#&OM\143E+^)<6@)2AF;!/M
M3X8R=E^.3,J%2Y9\\5<N-+%X$:+G+00PQ[X^!BZHG)"1X4>@B@9YLU$N^<WT
MXHLZS63V%7TR06+.CH/UO*'%V]'B&=J9#"3XFTNTQ [-MR+3SIJ8D>BL2!NU
MI[K1F@9%:</2R-Q@,3WI+M%KA2B62H!)*D%>%:%?(*C:HYT)R@!7^##F_!-.
MZ2^TZ@#2^90# $"IQ8A8B1T7K05BR152M?]BVF6-9/*K(C-RBI*WV*(<54B.
M*<.XM -_H@[/(!_3>V&#\>#!Q+S4:_HB@H)B2O.R:>:Q\/EO:IA*A-K(1C*^
M\*^O(C)2ZU/^0L!=5PP(O :I4E]=G]@0P%T0 +OQL/Y<;8K%1"5H<XWGLIBY
MP',Q_EK?3THK+X?TSYB41:*#'"# VH=#$BV4?&./!U$LO#HN<0XD]<9G9=YW
MHPVRV^#A8Z<?/81[S&!X/FF4>SEH,A:=XQPL;UN6M*P?_(JQP_8,Z4^)K'//
MYWG9B^2_$%^M$;:?SR#?N8=\[[T*_3Q3H0^ S%?/Y'D#AMX N[*SP7A?0M6Y
MHESEOVCZ(&N,$=1(A3WFX, &\3XHNC@+B++V8L[!M0962R%5?/4>7W<CP/90
MOO*< 8CWV7J4RY!$#KD7!#M:V+<B^WF9%;.:OU4)0YNTS;]SVN957,2-(]#<
M)737("C%Z<,$:0M/2#M[D&VF&)'XBQ&H&=-*$ISB*E4(875)R^R;Q4@TXAD2
ML:YV&K>X&X?SR5B^-4=PZ\$<BV=5)OQ<WX$H0 8:I2O[O_-9]A)#F 586*,/
M+ZEE/R;)B6XRF=0IVN2A*9N6D-M?OF@O1='S'=*\%;IF *#8!'UFO%T'$3A-
M(YM=S3EK@U>A=PL'Q&=@F";=:<3'77/F5CCJD3>$-CQ-:(TIK*PI&</;&M!V
M\V$/-Z'M@[?)D.O BB#R'5U>-XVSEC@9:1/G*KWG!5PT:QK.TAN8G>QA7[J>
MS1LOX6.5*<:YK2N0#A2'=_XU<%+#Y^&?3@_D099IW^:IZ,O^M".. ^M'58V8
MAO\FA/X2FVI\SU6W+X>6<.6R]_C^&0PI+L@-%;IAA-!4(Y 58F&0!PH]QIKM
M<VGN1F5"RT:#N6@MULG5EX4DE,I#$ =W&$=E_;U5%O##;JEX%@1/3KJ0,%9D
M:3YHK5%"7+GXT&LHU^ZB"C#5-;)TL6/BF8P41X9\?*B:HS:*S$A:-_I6NLJO
MQUB.LZKIS82O'_ ,+7!>H^T8A\.7RX*)@J)*2D$F?[WMZ\,5RJ?<:X _\#@4
MB>=RK@G__73<\5$K612*1)[OP*H3GY1*IE2;2ZU US[JV!%O "T65K*9"1Q(
M%7VZR63LUEBG\BZ%%F<IYRH!QI#(BQ$OE]X'S4DP:#B:>X[W@(8NXA/@(!8D
MOE4W?KW*38+W_#SKU/9CR>U*.$L/;4*\H)E=S?I]S@E^1>I'XV,?!*]=X0 C
MW5/1VSOZP3UO[]=:0[K+XF1"(%IX(HCZ%/$#*F?[JI@@W/%B'Q>].'J+A=C;
MJ_YXVMOROY[@>&\W_/&L(P(M>\3-[6!F3X4O'&EV.]WZ.?6=PGM32>!TMW;J
MTSM;2T\>Y$I]65;0_U(J6^% 09N1OKT,07=2;W%%4ATB6FYS[-TP!K/$!15&
M1E<E #'57W(#:]!KC%8[E>JTEZL'P06SA*]FGF$0>>";O#(2*A'[<&7G6^!Q
MRZFV-<>V"!)RKTNGU-=]IJN$0=5,%[@+(>"!YJZ:W%=PHOIDFRO0YU?<E(/!
M-__<R632N2#-?RECVR&XN_Y2C[]4D&:=^42VZ@R,?0EBWR""._^R#1.*V;@W
M.BK<:QJ.@A%:NKNFN-636+K.""T-GCQ^L7/$ &"LA]J@ 3L(\!XZ[Z Q/T17
MM[V_M]?>W]EM;[W8/\ LTI&MK?;!BUY[?_O%SH92;T>IQTWB],:$-,YZ2!8\
M2]S?6*%L,U3QH8-7$18 Q9S=K?U]+,GZ"18B<A#+SM".N;R?-!PGO:V?4+\%
M!KRCYEF_YA*[VJ!+(/2?L4/KV%'B[51+V*B8SLH^T,HI&%YD9A%U? - <$<;
M]'%!/?AI^^!H]:XR-\2Z=S3SQT7=2*/%>*+:X4*[QB87H;LS[W/!^3D= :3#
M_?!ZN]S?G6-1H1='E0:$_LOHKA&K@?(-?T(,I&K]BGJ\B1(C6F#?["-%Y"/D
MH(8],8C5)U73:S32(';_O70%F]S2A9H2OHTPB/A<^[>$JZ<8MI3?YN.2OZ3T
MRQ":$WG7F/ 91Z[N;RD%A,O &FU!>6,9>6"*!\#G(3/>=R?TJ)ZPW4G />,+
MFOUU\/99UX^J46/J2C2 YA&S/.,6T/367*9#MD,;#4^XESO4;GA'W6]R]IX0
MM.=&)/S*;&YS(+ZZK[&:HY0H:CB=-:'N"$(#I-[S-/AHV,)$IC]]5>7.K"@!
M/OM "%UZH#$@EGK#D][6]A:R,0B2,C7=@[SU>/@>&@!R_T\.80 =7;]GX1U]
M_$\ZO5#Q6;K^K[^V->4=?>UO?X_//$M=(=':Y^_QN<?(VA(?;$S2?982M5X^
MOH<:X?5/]'EF"SV8_DV!Z!7.2+CVW\F\3VKN'$VB_0[C:Z?!^T7CJ /*PHXP
MWNP/*52,++!O21M%O7Z[RC!)OM5UR H,._O,'-]Z#"_@N8K*W&\S^A/],_0N
MKH]P&R;BV.\PTSTXV.V(8V,:CVZ%*!,G C7>2)?34 N;^RZ/,@K)O5</DN$6
M@3]T B<;D7?X(!ZX[K/Z53H90=DXU#&'1I?HI1;I#+EB5;/(<*:OC":HMGBX
M:L&X?+PT\>)!Y0J=K'BVNH3QLW@4KM>HN:%)=;P$"%T\.K32+!X#WDR71D'V
M]N(A0,*E8R%#:,5QSFY8/EY@ZI='D:&(:/GS"'[^ON*K?0A[\6@A"> O70L#
M8^G8W.V<D:B)CV0.#W;859&S\[#+4NC6 E)4=M 2H=-3JH:<1C4[T?<!&E>U
MY:RR/KQGO-KO$TS"-%Q1(1,>N@PVZ?7MU93)>>R^8;WW!5>M4GDE0_-ZIL1!
MW7B5YC!\QBPN[DFD<K#43VP&G:IM+\,;F@W2F:5"F&Q82C)?"O9SRX*KPZX5
M&,3E?=X#JLPY(/S1=^2O,A/((#,DM\+;![[LQ/ \24?VD]\0T3>]O=J[MLE]
M>QBY;W>DK71:T8_P23EU[+U,_:](9'#^0$0?!'\V5!!D*UY/[R*U039TG7:,
M;<U ?WZWI?I"HGIV7(#5FJPTHUN9^Z;%.4?"4+K/'@CT[+0^9,UQ,Z+C$MY+
MH]F.YJC/=9Q"^O"Z\WZ+KA#'EG478!]X"V6]<^J<4^-:$$4J*W!'KL+VEZ3L
MC)RTV)T1JD3!<RC1\+6>?5.I;00(,W['M8/W>Y\.#'P'*!&>"XP%D0/WC,ZC
M,D&/YT@]"'?>=4E&?N.]V8Z(.H&K"&DS"SOP@8A\RE;8Y2&CN9KM\#Y/<[S1
M^TJ"\_W[0\<POTI?(Y@%25JG[3 Q!+)$\D]]#V]#/$&.FW0AN\!=U-\SV\$-
M"9;&.@Y4!U3(F9V\QQF*1FB0P3%/:)&S%^H]4'AOR 8(Y'WO+Z,1>[Q.L(4;
M*]R6WZ)5C:4I?=$X'G[-USY8<CE+QPKXM,K=O*+\99U#^JAIOO-8T$K\1!0E
M1U<6C:QG/&_J3?7^%]FK'ZI]]UKBY.W[&PZMW]V1V[UO/C3CYR?G6"/<BLT0
M]X.C-20-R =$:,<.V4?O2*(D*K_?H2Q1EF^H_<?:+]X1D2'C17HT2F/Y,Z16
M<)>U&K[F).[;-'8C,Z<.JU^.2'X3")D>:NZ&WN:;;H/\MGN=W6U\P,N"1E/$
MU8L#4.TP4'U>Q,OGMO<Z^]T75Y[>ZG2O/'?=8W</.@?[.S=Z[',><KZ @;L<
M;L:--%F.-/4/C[8?+<QGF*$NP28R!G0LX".KXM:'6Z++CZ@&\$V>PX-]SNNT
MSH2G.^W$V+V'/(U-M\H;^AZ?_G)E\US>TWS]GNJLD2O7L!_6/S>\FSLJ<0QA
M_]*UQ/MW7M/Z;5;.L2D?F=Y3\>G\&"4MV$0&O3![6[WN=\BFO?MH]+WIAWZC
M:;I_KD3K!380G3"RK\R]L>,',TUL239FV'R[)3X<>[:L,VY.N2; U=RX?4<9
MYG=*;-OWH#5/N)>HSR@YU8Z#0=S W)JJD_;8^YHY51R9'Q8EFZ<@CO=50[I3
MWKC]!.T[7$=\8K=1+'XFVNWNMK >C>S(]1'PJ"@RQX3"F7G\ ^EZ41S5Z7II
M-/+;\J1CYW\9NSSG7T#_[:J<ITV?)#NCXDY3H*^0!;<)IWX/Y>+/T:N!_J%9
M-:_^ U!+ 0(4 Q0    ( *9!+EK\.\]=O@\  +-S   0              "
M 0    !E8G,M,C R-3 Q,30N:'1M4$L! A0#%     @ ID$N6J5A(#%P @
M. <  !               ( ![ \  &5B<RTR,#(U,#$Q-"YX<V102P$"% ,4
M    " "F02Y:M%<L/V,*   460  %               @ &*$@  96)S+3(P
M,C4P,3$T7VQA8BYX;6Q02P$"% ,4    " "F02Y:J,V,%>0&   N,P  %
M            @ $?'0  96)S+3(P,C4P,3$T7W!R92YX;6Q02P$"% ,4
M" "F02Y:!6/<9+,:  !)F@  &0              @ $U)   <')E<W-R96QE
F87-E7S Q,30R,#(U+FAT;5!+!08     !0 % $<!   ?/P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>ebs-20250114_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ebs-20250114.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <startDate>2025-01-14</startDate>
            <endDate>2025-01-14</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0001367644</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-23">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2025-01-14</dei:DocumentPeriodEndDate>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2025-01-14</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-4">EMERGENT BIOSOLUTIONS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-5">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">001-33137</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-7">14-1902018</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-8">300 Professional Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-9">Gaithersburg</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-10">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-11">20879</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-12">240</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-13">631-3200</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-17">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-18">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-19">EBS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-20">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-21">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
